PP / MONOGRAPH 025 Peptide or related research compound

CJC-1295 With DAC

Discovery history, preclinical evidence, human studies, current FDA context, and the questions that still need to be answered.

Evidence is not equivalence.

Research on a named molecule does not establish that a catalog material is the studied drug product. Identity, sequence, salt, formulation, purity, sterility, route, labeling, and indication can change the scientific and regulatory conclusion.

ORIGIN / HISTORY

When was CJC-1295 With DAC first described?

CJC-1295, a long-acting growth-hormone-releasing-hormone analog linked to a drug-affinity complex, was in early human development by the mid-2000s; Teichman and colleagues published a randomized human study in 2006. [1]

PRECLINICAL EVIDENCE

What do animal and laboratory studies show?

Preclinical pharmacology may exist, but this registry does not treat animal or in-vitro findings as human outcomes. The literature map should be reviewed for the model, species, comparator, endpoint, and replication status. [2]

Translation limitCell and animal findings can generate mechanisms and safety signals, but they do not predict clinical benefit on their own.

CLINICAL EVIDENCE

Are there human studies?

Early-phase trials raised GH/IGF-1; development halted. The available human evidence is limited, mixed, indirect, indication-specific, or not independently replicated; it should not be generalized to an unverified catalog material. [2][4]

Check the live study registry ↗

U.S. REGULATORY STATUS

Is CJC-1295 With DAC FDA cleared or approved?

Drug terminology: FDA generally approves drug products; “clearance” is typically a medical-device pathway.

FDA’s current compounding materials identify safety or evidence concerns relevant to CJC-1295 With DAC or a related named substance. Category or nomination status is not drug approval. This page does not identify an FDA-approved product corresponding to this catalog name; verify current records directly with FDA. [5][6][7]

RESEARCH OUTLOOK

Where is the scientific promise?

The scientific promise of CJC-1295 With DAC is a hypothesis for further testing, not a demonstrated product benefit. Useful next steps would include independent replication, validated identity and purity, dose–response and toxicology work, pharmacokinetics, prespecified endpoints, and properly registered human trials before clinical conclusions are drawn. [2][4]

LIMITATIONS / PRECAUTIONS

What should professionals keep in view?

Non-pulsatile GH may be less physiologic; water retention; unapproved. [2]

Professional-use boundary

This page does not provide a diagnosis, treatment recommendation, protocol, dose, reconstitution instruction, route, or administration schedule. Any lawful program requires independent regulatory, quality, toxicology, and clinical review.

SOURCE REGISTER

References and live evidence maps

Primary papers support specific historical claims where available. PubMed and ClinicalTrials.gov links are live evidence maps, not proof that every result applies to the exact catalog material. FDA links should be rechecked because regulatory pages and product labels can change.